Anti-Drug Antibodies, Drug Levels, Interleukin-6 and Soluble TNF Receptors in Rheumatoid Arthritis Patients during the First 6 Months of Treatment with Adalimumab or Infliximab: A Descriptive Cohort Study
Grith Petersen Eng, Pierre Bouchelouche, Else Marie Bartels, Henning Bliddal, Klaus Bendtzen, Michael Stoltenberg
Dive into the research topics of 'Anti-Drug Antibodies, Drug Levels, Interleukin-6 and Soluble TNF Receptors in Rheumatoid Arthritis Patients during the First 6 Months of Treatment with Adalimumab or Infliximab: A Descriptive Cohort Study'. Together they form a unique fingerprint.